285 related articles for article (PubMed ID: 11803062)
21. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
[TBL] [Abstract][Full Text] [Related]
22. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.
Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO
Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456
[TBL] [Abstract][Full Text] [Related]
23. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of widely consumed botanicals as immunological adjuvants.
Ragupathi G; Yeung KS; Leung PC; Lee M; Lau CB; Vickers A; Hood C; Deng G; Cheung NK; Cassileth B; Livingston P
Vaccine; 2008 Sep; 26(37):4860-5. PubMed ID: 18640165
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Krug LM; Ragupathi G; Ng KK; Hood C; Jennings HJ; Guo Z; Kris MG; Miller V; Pizzo B; Tyson L; Baez V; Livingston PO
Clin Cancer Res; 2004 Feb; 10(3):916-23. PubMed ID: 14871967
[TBL] [Abstract][Full Text] [Related]
26. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
27. Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells.
Cappello S; Liu NX; Musselli C; Brezicka FT; Livingston PO; Ragupathi G
Cancer Immunol Immunother; 1999 Dec; 48(9):483-92. PubMed ID: 10602885
[TBL] [Abstract][Full Text] [Related]
28. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
29. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.
Zhang S; Graeber LA; Helling F; Ragupathi G; Adluri S; Lloyd KO; Livingston PO
Cancer Res; 1996 Jul; 56(14):3315-9. PubMed ID: 8764127
[TBL] [Abstract][Full Text] [Related]
30. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
31. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
32. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
[TBL] [Abstract][Full Text] [Related]
33. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.
Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877
[TBL] [Abstract][Full Text] [Related]
34. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
36. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells.
Zou W; Borrelli S; Gilbert M; Liu T; Pon RA; Jennings HJ
J Biol Chem; 2004 Jun; 279(24):25390-9. PubMed ID: 15047693
[TBL] [Abstract][Full Text] [Related]
37. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
[TBL] [Abstract][Full Text] [Related]
38. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
39. Specific immunization using keyhole limpet hemocyanin-ganglioside conjugates.
Jennemann R; Gnewuch C; Bosslet S; Bauer BL; Wiegandt H
J Biochem; 1994 Jun; 115(6):1047-52. PubMed ID: 7982880
[TBL] [Abstract][Full Text] [Related]
40. Antibody inducing polyvalent cancer vaccines.
Ragupathi G; Gathuru J; Livingston P
Cancer Treat Res; 2005; 123():157-80. PubMed ID: 16211870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
